Expanding capacity New England Peptide operates from two North American sites with significant operations in Kentucky, suggesting capacity to scale custom peptide synthesis and catalog peptide manufacturing for larger pharma, biotech, and academic clients.

Strategic acquisitions Recent integration with Peptides International and leadership additions indicate a growth trajectory and broader product catalog, creating cross-sell opportunities for complementary peptide standards, substrates, and inhibitors.

Broad product suite Offerings span custom synthesis, catalog peptides, labeled bioanalytical standards, enzymes substrates and inhibitors, enabling upsell across research pipelines from basic discovery to analytical development.

Financial footprint Revenue in the 10–25 million range with mid-size employee base positions the company as a scalable supplier for mid to large R&D budgets, ideal for contract manufacturing and long-term supplier partnerships.

Targeted partnerships Dual-brand strategy (New England Peptide and Peptides International) and high-profile leadership appointments suggest openness to strategic collaborations, licensing, and joint development deals with academia and biotech/pharma firms.